Loading market data...
Sat, 15 Aug 2026
12:18:31 pm
Sat, 15 Aug 2026
12:18:31 pm
Rudransh Sangwan
Published at: August 14, 2026, 8:41 AM
Synopsis
Tarsons Products shares surge 12% to a 52-week high as trading volumes rise, despite weak Q1 profit. Check revenue growth, margins, valuation and key factors driving the rally.
A laboratory equipment stock jumped more than 12% on August 14, reaching its 52 week high of ₹350 as buying activity picked up sharply. The supplied market data shows the stock trading at ₹350, up 11.88%, with market capitalisation at around ₹1,860 crore. Trading volumes were also strong, with more than 3.6 million shares changing hands according to the supplied market coverage. The latest rally comes even though the June 2026 quarter showed revenue growth but a decline in profitability, making the sharp price move an important development for investors tracking the stock.
The company operates in the labware and life sciences products market, supplying consumables, reusables and benchtop equipment to research organisations, academic institutions, pharmaceutical companies, diagnostic companies and hospitals. June 2026 sales increased 20.67% year on year to ₹110.24 crore, but net profit moved to a loss of ₹1.44 crore from a profit of ₹1.78 crore. TTM sales stand at ₹441 crore, while TTM net profit is ₹11 crore. The stock trades at a P/E of around 157, with ROCE at 4.56% and ROE at 2.38%. The recent share price recovery therefore needs to be viewed alongside the company's current earnings profile.
Loading chart...
The stock was trading at ₹350 in the supplied market data, up 11.88% and matching its 52 week high. The stock has gained 73.65% over six months and 1.04% over one year, while it remains down 57.47% over five years. The latest five-day return stands at 9.64%. The market capitalisation is around ₹1,860 crore, while the stock trades at a P/E of 157 and 2.76 times book value. ROCE stands at 4.56% and ROE at 2.38%.
| Metric | Value |
|---|---|
| Current Price | ₹350 |
| 52 Week High | ₹350 |
| 52 Week Low | ₹164 |
| Market Cap | ₹1,860 crore |
| P/E | 157 |
| Book Value | ₹119 |
| Price to Book | 2.76x |
| Dividend Yield | 0.00% |
| ROCE | 4.56% |
| ROE | 2.38% |
The June 2026 quarter recorded 20.67% year on year sales growth, with revenue increasing to ₹110.24 crore from ₹91.36 crore. Operating profit increased only 5.22% to ₹25.99 crore, causing the operating margin to fall to 23.58% from 27.04%. Profit before tax moved into a loss of ₹1.32 crore compared with a profit of ₹3.03 crore in June 2025. Net profit also declined to a loss of ₹1.44 crore from a profit of ₹1.78 crore, while EPS moved from ₹0.33 to -₹0.27. The results show that the recent revenue growth has not yet translated into stronger bottom-line performance.
| Metric | Jun 2026 | Jun 2025 | YoY Change |
|---|---|---|---|
| Sales | ₹110.24 crore | ₹91.36 crore | 20.67% |
| Operating Profit | ₹25.99 crore | ₹24.70 crore | 5.22% |
| OPM | 23.58% | 27.04% | -3.46 ppt |
| Profit Before Tax | -₹1.32 crore | ₹3.03 crore | Loss |
| Net Profit | -₹1.44 crore | ₹1.78 crore | Loss |
| EPS | -₹0.27 | ₹0.33 | Loss |
The quarterly financial data also shows depreciation of ₹27.02 crore and interest expense of ₹6.27 crore in June 2026. These costs, along with the lower operating margin, contributed to the movement from profit to loss at the net profit level.
The long term numbers show that sales have grown while profitability has weakened considerably. Sales increased from ₹229 crore in March 2021 to ₹423 crore in March 2026 and ₹441 crore on a TTM basis. Operating profit increased from ₹103 crore in March 2021 to ₹118 crore in March 2026 and ₹119 crore on a TTM basis. Net profit, however, declined from ₹69 crore in March 2021 to ₹14 crore in March 2026 and ₹11 crore on a TTM basis. Five-year sales growth stands at 13% CAGR, while five-year profit growth is negative 26%.
| Financial Metric | Mar 2021 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | ₹229 crore | ₹423 crore | ₹441 crore |
| Operating Profit | ₹103 crore | ₹118 crore | ₹119 crore |
| Operating Margin | 45% | 28% | 27% |
| Profit Before Tax | ₹92 crore | ₹22 crore | ₹18 crore |
| Net Profit | ₹69 crore | ₹14 crore | ₹11 crore |
| EPS | ₹3,583.25* | ₹2.69 | ₹2.09 |
*The March 2021 EPS figure is reproduced exactly as supplied in the source data.
Sales have grown at 13% CAGR over five years and 11% on a TTM basis. Profit growth has moved in the opposite direction, with a 26% decline over five years and a 57% decline on a TTM basis. ROE stands at 5% over three years and 2% in the latest year. The stock's recent six-month gain of 73.65% therefore comes after a much longer period of weak share price performance, with the five-year return still at -57.47%.
The latest rally has been accompanied by heavy trading activity and buying momentum. The supplied market coverage points to trading volumes of more than 3.6 million shares and renewed investor interest in the life sciences and laboratory consumables segment. The broader focus on domestic manufacturing and stabilisation in laboratory plasticware and healthcare research demand has also been cited as a factor behind the market interest. However, these factors have not yet translated into a clear improvement in the latest bottom-line results.
The stock trades at a P/E of around 157 and 2.76 times book value, while ROCE is 4.56% and ROE is 2.38%. This places the current earnings valuation at a high level relative to the company's present profit generation. Investors should watch whether the 20.67% quarterly sales growth can lead to better operating profit and margins in future quarters. The movement in operating margin from 27.04% to 23.58% in June 2026 is also important, as is the company's ability to return to consistent net profitability.
The main financial concern is the weak conversion of revenue growth into earnings. June 2026 sales increased more than 20%, but operating profit rose only 5.22% and net profit moved into a loss. TTM net profit is only ₹11 crore, while the stock trades at a P/E of around 157. Low ROE and ROCE are also factors to monitor. The stock has gained more than 73% in six months, so future earnings performance will be important in assessing whether the recent price recovery can continue.
The latest trading session shows strong buying momentum, with the stock rising 11.88% to its 52 week high of ₹350. At the same time, the June quarter remains mixed, with sales rising 20.67% but net profit moving to a loss of ₹1.44 crore and operating margin falling to 23.58%. TTM sales have reached ₹441 crore, while TTM net profit stands at only ₹11 crore. The next few quarters will be important for determining whether the recent recovery in demand and sales can translate into stronger margins and sustainable profits.
Tarsons Products Ltd operates in the laboratory equipment and labware sector. The company designs, develops, manufactures and markets laboratory consumables, reusables and other products, including benchtop equipment and instruments. Its products are used across research organisations, academic institutions, pharmaceutical companies, Contract Research Organisations, diagnostic companies and hospitals. The company is classified under Healthcare Equipment & Supplies and Medical Equipment & Supplies.
Tarsons Products was trading at around ₹350 in the supplied August 14, 2026 market data, up 11.88% during the session and matching its reported 52-week high.
Tarsons Products shares rose sharply amid strong buying momentum and high trading volumes. The supplied market information points to renewed interest in the life sciences and laboratory consumables segment, along with expectations around stabilising demand and domestic manufacturing.
Tarsons Products' supplied 52-week high is ₹350, while its 52-week low is ₹164.
Tarsons Products reported June 2026 sales of ₹110.24 crore, up 20.67% from ₹91.36 crore in June 2025.
Tarsons Products reported a net loss of ₹1.44 crore in June 2026, compared with a net profit of ₹1.78 crore in the corresponding quarter.
Tarsons Products reported an operating margin of 23.58% in June 2026, compared with 27.04% in June 2025.
Tarsons Products is trading at a P/E ratio of approximately 157, based on the supplied August 14 market data.
Tarsons Products has a market capitalisation of approximately ₹1,860 crore based on the supplied market data.
Tarsons Products manufactures laboratory consumables, reusables and benchtop equipment used by research organisations, pharmaceutical companies, diagnostic companies, hospitals and academic institutions.
Tarsons Products has an ROE of approximately 2.38% based on the supplied market data. The company's three-year ROE is reported at around 5%.
Tarsons Products has an ROCE of approximately 4.56% based on the supplied market data.
Tarsons Products has delivered a -57.47% five-year return based on the supplied historical stock-return data, despite gaining 73.65% over the last six months.
Investors should watch revenue growth, operating margins, quarterly profitability and the company's ability to improve returns on capital. The current valuation is also an important factor, given the P/E of around 157.
Yes. Tarsons Products was trading at around ₹350, matching its supplied 52-week high of ₹350 after the sharp August 14 rally.
Financial journalist specializing in market analysis, stock research, and investment trends. Dedicated to providing accurate, timely insights for informed decision-making.
Credentials: Experienced financial journalist with expertise in equity markets and economic analysis
The information provided in this article is for educational and informational purposes only and should not be construed as financial, investment, or legal advice. welomoney does not provide personalized investment recommendations.
For detailed terms and conditions, please read our Disclaimer and Terms of Service.
Petronet LNG's Q1FY27 EBITDA rose 26% as Nomura retained its Rs 345 target and Buy rating, with volume recovery expected from 4QFY27.
Indian media and entertainment sector stock jumps 8% after SAT grants interim relief in a SEBI case, clearing a path for a ₹3,143 crore promoter...
Aerospace and defence business sees a sharp Q1 FY27 revenue jump as acquisitions, global partnerships and major defence orders reshape its growth...
Passenger vehicle stock falls nearly 6% after Q1 profit drops 78.54% to ₹859 crore. Revenue rises 9%, while JLR headwinds weigh on earnings and...
Manorama Industries shares hit a fresh 52-week high after Q1 FY27 profit jumped 67.6%, with revenue rising 39.5% on strong demand and higher capacity.
